Biobank for bronchial cancer patients to support research
Official title: Development of a Prospective Monocentric Clinico-Biological Database for Bronchial Cancer
Run by Institut du Cancer de Montpellier - Val d'Aurelle · NCT07085429 · Data updated 2026-11-12
A biobank project will collect blood and tissue samples from adults with bronchial cancer to help researchers study biology and improve future treatments.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 750 (estimated) |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Montpellier, France) |
| Status | Recruiting |
| Started | November 25, 2025 |
| Main results expected | September 2030 |
| Study ends | September 2040 |
| Registry record updated | November 6, 2026 |
| Trial ID | NCT07085429 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with histologically or cytologically confirmed bronchial cancer who have not yet begun treatment for their current cancer and who can provide informed consent.
✕Probably not a fit
Patients who do not consent or who have conditions preventing follow-up or sample collection may not benefit from this resource.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project creates a tissue and blood biobank from patients with bronchial carcinoma, including both small-cell and non-small-cell types, treated at a single center in Montpellier. Samples are collected with informed consent from treatment-naïve adults and stored to support analytical and epidemiological research as well as development of new therapies. It aims to deepen understanding of how histological and molecular differences influence prognosis and response to therapy. The study does not involve a therapeutic intervention beyond sample collection. It is designed to enable future clinical research and trial development by providing high-quality biological material linked to clinical data.
Why it matters
Potential benefit: If successful, the biobank could accelerate discovery of biomarkers and guide future personalized treatment strategies for bronchial cancer.
How similar studies have gone: Biobanks in lung cancer and other cancers have supported numerous translational studies and some therapeutic advances, though this exact bronchial cancer biobank is a targeted, center-specific initiative.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female patient aged over 18 years, * Histologically or cytologically confirmed bronchial cancer, * Treatment-naïve patient for the current cancer, * Patient who has provided informed, written, and explicit consent, * Patient affiliated with the French national health insurance system. Exclusion Criteria: * Patient with a WHO performance status ≥ 3, * Pregnant and/or breastfeeding woman, * Patient with a history of other cancers within the 5 years preceding inclusion, * Patient for whom regular follow-up is considered impossible due to psychological, familial, social, or geographic reasons, * Patient under legal protection (guardianship, curatorship, or judicial protection).
Where it's running
-
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France, France Recruiting
Study contacts
- Study coordinator: Emmanuelle TEXIER
- Email: emmanuelle.texier@icm.unicancer.fr
- Phone: 467613102
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.